RLAY · Relay Therapeutics, Inc.

Current Thesis

The binary fired, and it fired up. Through April the name was an undecided pre-data setup split coverage ($18 Jones Hold vs. $21 Barclays Overweight) into a Q1 print and an ASCO readout. Both are now past, and the data validated the franchise. Zovegalisib (the molecule formerly carried as RLY-2608) posted ~11-month median PFS in CDK4/6-experienced PIK3CA-mutant HR+/HER2- breast cancer, the FDA granted Breakthrough Therapy Designation, and the balance sheet funds operations into 2029. The stock surged ~20% on ASCO momentum (May 29–June 2) to a 52-week high of $17.33, and the sell-side re-rated to $26–$28. The leg an investor buys here is the post-data re-rate of a de-risked, regulatorily-blessed PI3Kα franchise toward those new targets. The catch: entry is extended after a +348% trailing-twelve-month run, the big clinical binary has already been spent, and the next hard catalyst (Phase 3 ReDiscover-2) sits in 2027. Accelerating narrative, late entry point.

Bull Case

• FDA Breakthrough Therapy Designation for zovegalisib + fulvestrant (PIK3CA-mutant HR+/HER2- advanced breast cancer, post-CDK4/6i), disclosed alongside Q1 on 2026-05-05 the single biggest de-risking event in the program's history, opening a potential accelerated/registrational path.
• Efficacy bar cleared: ~11.1-month median PFS in CDK4/6-experienced patients (kinase-domain 11.2mo, non-kinase 11.0mo), with the ReDiscover Phase 1/2 showing 39% ORR (n=31 measurable) and 10.3-month mPFS (n=52). That roughly doubles the ~5.5-month alpelisib+fulvestrant SOLAR-1 benchmark and supports a best-in-class read on the mutant-selective mechanism (lower hyperglycemia vs. Novartis's Piqray).
• Funded into 2029: $642.1M cash/investments at 3/31/26 (Q1 print 2026-05-05), removing the dilution overhang that caps clinical-biotech multiples. The Phase 3 is paid for.
• Sell-side re-rating: Guggenheim Buy PT $26 and HC Wainwright Buy PT $28, both 2026-05-26, up from the April $18–$21 band. Targets now sit ~55–65% above the ~$16.85 spot the split coverage resolved decisively upward.
• Pipeline optionality: Phase 3 ReDiscover-2 ongoing; zovegalisib + atirmociclib triplet selected for 1L with a Phase 3 planned early 2027 extends the franchise beyond the 2L+ entry indication.
• Tape confirms the fundamental: +20% on ASCO to a 52-week high $17.33, +348% trailing-12-month total return. In a momentum book, strength near highs on validated data is confirmation.

Bear Case

• The big binary is already behind it. ASCO 2026 (May 29–June 2) and the Q1 print (2026-05-05) are spent; a fresh buyer at a 52-week high is positioning into the post-event air pocket, with no company-specific catalyst until Phase 3 milestones in 2027.
• Valuation is stretched on a pre-revenue, single-franchise story: $3.11B market cap, Q1 revenue of just $3.0M (down from $7.7M a year prior), net loss $73.3M. InvestingPro flagged shares above fair value (June 2026). Value is entirely terminal and Phase-3-dependent.
• The "no forced raise" framing held only because the company issued equity into strength $137.1M of the $642.1M cash came from at-the-market sales. Continued ATM use on rallies caps upside.
• Competition is closing the differentiation gap: selective PI3Kα programs from Scorpion (STX-478) and Lilly target the same mutant-selective niche. A rival printing comparable PFS with cleaner safety before ReDiscover-2 reads would erode the best-in-class claim instantly.
• Single-asset concentration: zovegalisib is effectively the whole equity. RLY-4008 (FGFR2) was licensed to Elevation Oncology, so a Phase 3 stumble has no offsetting catalyst.
• Precision-oncology trades historically fade the data event ("buy the abstract, sell the oral"); the ASCO oral is now public, so near-term flows are positioning-driven and exposed to XBI sector beta.

Setup & Price Structure

• Spot ~$16.85 (June 2026), just under the 52-week high $17.33 printed on the ASCO surge; market cap ~$3.11B.
• Analyst band stepped up hard: $26 (Guggenheim) / $28 (HC Wainwright) on 2026-05-26, versus $18 (Jones) / $21 (Barclays) in April. Spot trades ~35% above the old ceiling and ~55–65% below the refreshed targets the gap to PT is the bull's runway, the gap to old support is the risk.
• Breakout structure: the data move cleared the ~$14 pre-ASCO consolidation shelf, which becomes first support. The rising post-breakout 20-EMA is the momentum line to watch.
• Trend is extended after the +348% trailing-twelve-month total return; chasing the 52-week high carries reversion risk. The cleaner continuation entry is a higher-low retest of the $14–$15 breakout shelf that holds the rising 20-EMA, rather than buying the high tick.
• Confirmation for a fresh momentum probe: holds above the breakout shelf and the rising 20-EMA on contracting pullback volume. Failure: a weekly close back under $14 — that round-trips the data move.

Catalyst Calendar (next 30 days)

• No confirmed company-specific binary inside the 2026-06-07 → 2026-07-07 window both scheduled catalysts (Q1 print 2026-05-05; ASCO 2026 May 29–June 2) are past.
• Unscheduled, date-unspecified: FDA registrational-path / Type B meeting feedback following the Breakthrough designation (granted ~2026-05-05) could surface as an 8-K at any time. This is the live near-term swing factor.
• Phase 3 ReDiscover-2 enrollment/interim updates no fixed date; readout cadence points to 2027.
• ~Early August 2026 (est.): Q2 2026 earnings next scheduled cash/burn/enrollment checkpoint, outside the 30-day window.
• Sector overlay: XBI/biotech beta and any FDA macro headlines dominate price action absent company news through this window.

What Would Change Our Mind

• A weekly close below $14 round-trips the post-ASCO breakout and the pre-data consolidation shelf the re-rate failed and the data move was fully faded.
• A competing selective PI3Kα program (Scorpion STX-478, Lilly) reporting ≥11-month PFS with comparable or cleaner safety before ReDiscover-2 reads removes the best-in-class differentiation.
• A Q2 print (~early August) showing quarterly cash burn accelerating materially above the ~$80M Q1 run-rate, or heavier ATM issuance, reintroduces the dilution overhang the cash-into-2029 story removed.
• Any FDA setback on the registrational path (clinical hold, refuse-to-file signal, BTD-related disappointment) breaks the regulatory leg of the thesis.
• XBI losing its 200DMA flips small-cap binary biotech risk-off regardless of the company-specific setup.

Correlation Notes

• Theme cohort: biotech-precision-therapeutics, specifically the PI3Kα HR+/HER2- breast-cancer complex. Co-moves with mutant-selective PI3Kα peers (Scorpion) and against the displaced incumbent benchmark, Novartis's alpelisib (Piqray).
• Sector beta: high small-cap clinical-biotech beta to XBI; the XBI 200DMA functions as the risk-on/off line. Long-duration cash-flow profile makes it rate-sensitive it tends to move inversely with real yields and the 10Y.
• Idiosyncratic dominance: a near single-asset name, so clinical and FDA headlines override sector correlation around data prints the XBI relationship decouples on event days. A history of elevated short interest adds squeeze sensitivity to positive surprises.
• Low correlation to the AI/mega-cap complex; this is a clinical-data-and-FDA-calendar instrument, not a macro-growth proxy.